Skip to main content
Top
Published in: Journal of Community Health 2/2017

01-04-2017 | Original Paper

Adherence to ACIP Recommendation for Human Papillomavirus Vaccine Among US Adolescent Girls

Authors: Mahbubur Rahman, Jacqueline M. Hirth, Abbey B. Berenson

Published in: Journal of Community Health | Issue 2/2017

Login to get access

Abstract

The objective of this study was to examine correlates of human papillomavirus (HPV) vaccine use according to Advisory Committee on Immunization Practices (ACIP)’s recommendations among US adolescent girls. We used National Immunization Survey of Teens 2013 data. Based on provider-verified (n = 9403) information, 57.3, 39.1 and 19.0 % of adolescent girls, initiated, completed and completed the HPV vaccine according to ACIP’s recommendation (by age 12), respectively. Hispanic race/ethnicity, a physician recommendation for HPV vaccine and ≥1 influenza vaccine in the past 3 years were all associated with a higher likelihood of compliance with ACIP’s recommendation. Girls from a larger family and those whose immunization provider was a STD/school/teen clinic were less likely to receive the vaccine at the recommended age compared to a girl raised in a smaller sized family and received immunization from a hospital facility, respectively. Only one-fifth of 13–17 yo girls receive the HPV vaccine by age 12 as recommended by ACIP. Physician visits and influenza vaccination settings are opportunities to improve vaccine series completion at the recommended age.
Literature
1.
go back to reference Garland, S. M., Steben, M., Sings, H. L., et al. (2009). Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. Journal of Infectious Diseases, 199(6), 805–814.CrossRefPubMed Garland, S. M., Steben, M., Sings, H. L., et al. (2009). Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. Journal of Infectious Diseases, 199(6), 805–814.CrossRefPubMed
2.
go back to reference Bosch, F. X., Burchell, A. N., Schiffman, M., et al. (2008). Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine, 26(Suppl 10), K1–K16.CrossRefPubMed Bosch, F. X., Burchell, A. N., Schiffman, M., et al. (2008). Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine, 26(Suppl 10), K1–K16.CrossRefPubMed
3.
go back to reference Joura, E. A., Giuliano, A. R., Iversen, O. E., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, 372(8), 711–723.CrossRefPubMed Joura, E. A., Giuliano, A. R., Iversen, O. E., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, 372(8), 711–723.CrossRefPubMed
4.
go back to reference Reagan-Steiner, S., Yankey, D., Jeyarajah, J., et al. (2015). National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 Years: United States, 2014. MMWR Morbidity Mortality Weekly Report, 64(29), 784–792.CrossRefPubMed Reagan-Steiner, S., Yankey, D., Jeyarajah, J., et al. (2015). National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 Years: United States, 2014. MMWR Morbidity Mortality Weekly Report, 64(29), 784–792.CrossRefPubMed
5.
go back to reference Hopkins, T. G., & Wood, N. (2013). Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes. Vaccine, 31(13), 1673–1679.CrossRefPubMed Hopkins, T. G., & Wood, N. (2013). Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes. Vaccine, 31(13), 1673–1679.CrossRefPubMed
6.
go back to reference Markowitz, L. E., Dunne, E. F., Saraiya, M., Centers for Disease Control and Prevention (CDC). et al. (2014). Human papillomavirus vaccination: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recommendation Report, 63(RR-05), 1–30. Markowitz, L. E., Dunne, E. F., Saraiya, M., Centers for Disease Control and Prevention (CDC). et al. (2014). Human papillomavirus vaccination: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recommendation Report, 63(RR-05), 1–30.
7.
go back to reference Lehtinen, M., Paavonen, J., Wheeler, C. M., et al. (2012). Overall efficacy of HPV-16/18 AS04 adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, 13(1), 89–99.CrossRefPubMed Lehtinen, M., Paavonen, J., Wheeler, C. M., et al. (2012). Overall efficacy of HPV-16/18 AS04 adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, 13(1), 89–99.CrossRefPubMed
8.
go back to reference Block, S. L., Nolan, T., Sattler, C., et al. (2006). Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics, 118(5), 2135–2145.CrossRefPubMed Block, S. L., Nolan, T., Sattler, C., et al. (2006). Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics, 118(5), 2135–2145.CrossRefPubMed
9.
go back to reference Pedersen, C., Petaja, T., Strauss, G., et al. (2007). Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. Journal of Adolescent Health, 40(6), 564–571.CrossRefPubMed Pedersen, C., Petaja, T., Strauss, G., et al. (2007). Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. Journal of Adolescent Health, 40(6), 564–571.CrossRefPubMed
10.
go back to reference Dunne, E. F., Unger, E. R., Sternberg, M., et al. (2007). Prevalence of HPV infection among females in the United States. Journal of American Medical Association, 297(8), 813–819.CrossRef Dunne, E. F., Unger, E. R., Sternberg, M., et al. (2007). Prevalence of HPV infection among females in the United States. Journal of American Medical Association, 297(8), 813–819.CrossRef
11.
go back to reference Rahman, M., McGrath, C. J., Hirth, J. M., & Berenson, A. B. (2015). Age at HPV vaccine initiation and completion among US adolescent girls: Trend from 2008 to 2012. Vaccine, 33(5), 585–587.CrossRefPubMed Rahman, M., McGrath, C. J., Hirth, J. M., & Berenson, A. B. (2015). Age at HPV vaccine initiation and completion among US adolescent girls: Trend from 2008 to 2012. Vaccine, 33(5), 585–587.CrossRefPubMed
13.
go back to reference Jain, N., Singleton, J. A., Montgomery, M., & Skalland, B. (2009). Determining accurate vaccination coverage rates for adolescents: The National Immunization Survey-Teen 2006. Public Health Reports, 124(5), 642–651.CrossRefPubMedPubMedCentral Jain, N., Singleton, J. A., Montgomery, M., & Skalland, B. (2009). Determining accurate vaccination coverage rates for adolescents: The National Immunization Survey-Teen 2006. Public Health Reports, 124(5), 642–651.CrossRefPubMedPubMedCentral
14.
go back to reference Kahn, J. A., Ding, L., Huang, B., Zimet, G. D., Rosenthal, S. L., & Frazier, A. L. (2009). Mothers’ intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses. Pediatrics, 123(6), 1439–1445.CrossRefPubMed Kahn, J. A., Ding, L., Huang, B., Zimet, G. D., Rosenthal, S. L., & Frazier, A. L. (2009). Mothers’ intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses. Pediatrics, 123(6), 1439–1445.CrossRefPubMed
15.
go back to reference Daley, M. F., Crane, L. A., Markowitz, L. E., et al. (2010). Human papillomavirus vaccination practices: A survey of US physicians 18 months after licensure. Pediatrics, 126(3), 425–433.CrossRefPubMed Daley, M. F., Crane, L. A., Markowitz, L. E., et al. (2010). Human papillomavirus vaccination practices: A survey of US physicians 18 months after licensure. Pediatrics, 126(3), 425–433.CrossRefPubMed
16.
go back to reference Vadaparampil, S. T., Kahn, J. A., Salmon, D., et al. (2010). Missed clinical opportunities: Provider recommendations for HPV vaccination for 11–12 year old girls are limited. Vaccine, 29(47), 8634–8641.CrossRef Vadaparampil, S. T., Kahn, J. A., Salmon, D., et al. (2010). Missed clinical opportunities: Provider recommendations for HPV vaccination for 11–12 year old girls are limited. Vaccine, 29(47), 8634–8641.CrossRef
17.
go back to reference Dempsey, A., Cohn, L., Dalton, V., & Ruffin, M. (2010). Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine, 28(4), 989–995.CrossRefPubMed Dempsey, A., Cohn, L., Dalton, V., & Ruffin, M. (2010). Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine, 28(4), 989–995.CrossRefPubMed
Metadata
Title
Adherence to ACIP Recommendation for Human Papillomavirus Vaccine Among US Adolescent Girls
Authors
Mahbubur Rahman
Jacqueline M. Hirth
Abbey B. Berenson
Publication date
01-04-2017
Publisher
Springer US
Published in
Journal of Community Health / Issue 2/2017
Print ISSN: 0094-5145
Electronic ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-016-0267-6

Other articles of this Issue 2/2017

Journal of Community Health 2/2017 Go to the issue